BioMarin Pharmaceutical (BMRN) late Wednesday reported Q4 non-GAAP earnings of $0.92 per diluted share, compared with $0.49 a year earlier.
Analysts polled by FactSet expected $0.74.
Revenue for the quarter ended Dec. 31 was $747.3 million, compared with $646.2 million a year earlier.
Analysts polled by FactSet expected $712.3 million.
For 2025, the company is projecting non-GAAP EPS of $4.20 to $4.40 on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet are looking for $4.15 and $3.10 billion, respectively.
BioMarin shares recently were up 8.2% in Wednesday's after-hours session.
Price: 71.00, Change: +5.39, Percent Change: +8.22
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。